The invention relates to purinergic (P2X) receptors, more specifically to P2X7receptors, the generation of antibodiesand the use of antibodies and immunogens that are capable of selectivelybinding to a non ATP-binding P2X7 receptor but not to anATP-binding P2X7 receptor, for the detection and treatment of diseaseconditions, especially cancer.